Accord Healthcare Ltd.

The latest meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use has seen Accord Healthcare win positive opinions for its two denosumab biosimilars, at the same tim

Vyjuvek (beremagene geperpavec), Krystal Biotech’s topical gene therapy for the rare genetic skin disorder, dystrophic epidermolysis bullosa (DEB), could be approved for use across the EU soon, after

Amgen’s biosimilar version of Eylea (aflibercept) and Aurobindo’s Neulasta (pegfilgrastim) rival have been lined up for pan-European marketing authorizations, after the European Medicines Agency’s Com

Coherus BioSciences has been transitioning from a focus on biosimilars to developing and commercializing its own immuno-oncology therapies – led by anti-PD-1 agent Loqtorzi (toripalimab-tpzi) – and it